$RDY

Analysts' average price target for Dr. Reddy's Laboratories Ltd (RDY) decreased from $13.24 to $13.12, suggesting a 1% downside from the Oct. 23 close. The consensus rating remains 'Hold' among 39 analysts.

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia

Dr. Reddy's Laboratories (NYSE: RDY) expects to relaunch semaglutide in November 2026, with most supply going to Canada. Q2 North America generics revenue was $264M, down 29% YoY. The company received FDA approval for its rituximab biosimilar and launched nivolumab in India. Net cash as of Sept. 30 was INR 2,502 crore, with full-year capex expected at INR 1,600-1,700 crore.

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

Dr Reddy's Laboratories' US subsidiary received a $32,350 IRS penalty for misclassifying its fiscal year. The company stated this has no material financial impact. Separately, the USFDA issued two observations after an assessment of its Mexico API facility. Shares closed 2.51% lower on October 1, 2026.

Dr Reddy's Laboratories has signed a royalty-free licensing agreement with Gilead Sciences to manufacture and supply investigational once-yearly lenacapavir for HIV prevention in 120 countries. The drug is currently in Phase 3 clinical trials and not yet approved. This expands their existing partnership for twice-yearly lenacapavir, which is approved by USFDA, EMA, and recommended by WHO. The agreement aims to support manufacturing and supply planning in high-incidence, low- and lower-middle-inc

GLP-1 drug sales in Canada are on track to reach $4.8 billion in 2026, up from $3.9 billion in 2025. Novo Nordisk's Ozempic led with $1.49 billion in sales, followed by Wegovy, Mounjaro, and Zepbound. Generic versions from Apotex and Dr. Reddy's had modest sales. IQVIA Canada provided the data.

Dr. Reddy’s Laboratories said the US FDA completed a GMP inspection of its Bachupally, Hyderabad formulations facility (FTO-3) from Aug 6 to Aug 14, 2026. The company received a Form 483 listing four observations and plans to address them within the required timeline.

Dr. Reddy’s Laboratories said the US FDA concluded a GMP inspection of its API manufacturing facility in Mirfield, UK. The agency classified the outcome as “Voluntary Action Indicated (VAI)” and closed the inspection under 21 CFR 20.64(d)(3). The update is intended for stakeholder records.

Dr. Reddy’s Laboratories said the US FDA inspected its Hyderabad formulations facility FTO-3 (Bachupally) from Aug 6-14, 2026 and issued a Form 483 listing four observations. The company must prepare and implement a remediation plan within the US FDA’s timeline. Investors may watch for updates on corrective actions and closure.